Molecular Biology and Therapeutics in Musculoskeletal Oncology (MBTMO) Research S

简介(申请人提供)：美国整形外科医生学会(AAOS)致力于服务于骨科专业，维护患者的利益，促进最高质量的肌肉骨骼健康。AAOS是世界上为骨科外科医生和其他人提供肌肉骨骼教育的卓越供应商。AAOS也是改善病人护理的倡导者，并向公众宣传骨科科学。AAOS于1933年在西北大学成立，是一个非营利性组织，从一个成员不到500人的小组织发展成为世界上最大的肌肉骨骼专家医学协会。该学院目前在国际上为3万多名成员提供服务。AAOS与许多杰出的研究人员一起参与了骨科尖端信息的开发和呈现。 AAOS研究研讨会代表了科学院、政府机构、行业、专业学会、整形外科研究和教育基金会(OREF)、整形外科研究学会(ORS)、领先研究人员和临床医生之间长期合作的历史。一年一度的研究研讨会旨在根据科学证据确定选定主题领域的知识库，找出知识库中的差距，并概述未来的研究机会。研讨会为专家提供了交流信息的机会，并通过科学陈述和积极的讨论小组开展合作努力。 2008年9月25日至27日举行的AAOS/ORS肌肉骨骼肿瘤学分子生物学和治疗学(MBTMO)研究研讨会将定义肌肉骨骼肿瘤学的最新研究成果，并确定未来的研究方向。具体地说，MBTMO研讨会将确定肌肉骨骼肿瘤学重要领域的临床和生物学研究和实践的现状，包括肿瘤生物学、当前治疗/限制/抗药性、骨肉瘤的生物治疗、尤文氏肉瘤的生物治疗、软骨肉瘤的生物治疗、软组织肉瘤的生物治疗、疾病易感性和新疗法的基因组筛选技术、新疗法/策略/管理问题以及组织缺陷和转移疾病的管理。研讨会将确定将实验室研究转化为临床实践的需求和机会，刺激研究议程，并向肌肉骨骼界提供教育，包括通过与《骨与关节外科杂志》(JBJS)的现有关系及时发表摘要文章的形式的执业医生和年轻研究人员，在AAOS网站上，以及癌症特定的组织和团体。研讨会将促进肌肉骨骼医学、行业和政府领域的利益攸关方之间的互动。MBTMO联席主席确保将少数族裔、妇女和残疾人作为教职员工和特邀嘉宾包括在内。

DESCRIPTION (provided by applicant): The American Academy of Orthopaedic Surgeons (AAOS) strives to serve the orthopaedic profession, champion the interests of patients, and advance the highest quality musculoskeletal health. The AAOS is the preeminent provider of musculoskeletal education to orthopaedic surgeons and others in the world. The AAOS also serves as an advocate for improved patient care and informs the public about the science of orthopaedics. Founded at Northwestern University as a not-for-profit organization in 1933, the AAOS has grown from a small organization serving less than 500 members to the world's largest medical association of musculoskeletal specialists. The Academy now serves more than 30,000 members internationally. The AAOS has been involved with many outstanding researchers in the development and presentation of information on the "cutting edge" of orthopaedics. The AAOS Research Symposia represent a long history of collaboration between the Academy, governmental agencies, industry, specialty societies, the Orthopaedic Research and Education Foundation (OREF), the Orthopaedic Research Society (ORS), leading researchers, and clinicians. The annual research symposia are designed to define the knowledge base in a chosen topic area based on scientific evidence, to identify gaps in the knowledge base, and to outline future research opportunities. The symposia provide an opportunity for experts to exchange information and develop collaborative endeavors through scientific presentations and active discussion groups. The 2008 AAOS/ORS Molecular Biology and Therapeutics in Musculoskeletal Oncology (MBTMO) Research Symposium, September 25-27, 2008, will define the state-of-the-art as it pertains to musculoskeletal oncology and identify future research directions. Specifically, the MBTMO symposium will identify the current status of clinical and biological research and practice in important areas of musculoskeletal oncology, including Tumor Biology, Current Treatment/Limitations/Resistance to Treatment, Biologic Based Therapy for Osteosarcoma, Biologic Based Therapy for Ewing's Sarcoma, Biologic Based Therapy for Chondrosarcoma, Biologic Based Therapy for Soft Tissue Sarcoma , Genomic Screening Techniques for Disease Susceptibility and New Treatments, Novel Therapies/Strategies/Regulatory Issues, and Management of Tissue Defects and Metastatic Disease. The symposium will define needs and opportunities for translating laboratory research into clinical practice, stimulate the research agenda, and provide education to the musculoskeletal community, including practicing physicians and young investigators in the form of timely summary article publication through an existing relationship with the Journal of Bone and Joint Surgery (JBJS), on the AAOS website, and to cancer-specific organizations and groups. The symposium will promote interaction between stakeholders in the area of musculoskeletal medicine, industry and government. The MBTMO co-chairs ensure the inclusion of minorities, women, and persons with disabilities both as faculty and as invited guests.